Search Results for "Lipids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lipids. Results 131 to 140 of 149 total matches.

Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
% with risankizumab 360 mg, and 2.1% with placebo. Lipid elevations have been reported with the drug. Serious ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):205-7 |  Show IntroductionHide Introduction

Pioglitazone/Metformin (Actoplus met)

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2006  (Issue 1227)
of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes ...
For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination (Actoplus met - Takeda) of two widely used antihyperglycemic drugs, the thiazolidinedione pioglitazone (Actos) and the biguanide metformin (Glucophage, and others), has been approved by the FDA for management of type 2 diabetes. It is indicated for patients already being treated with both pioglitazone and metformin or as second-line therapy for those not adequately controlled with either metformin or pioglitazone alone....
Med Lett Drugs Ther. 2006 Jan 30;48(1227):9-11 |  Show IntroductionHide Introduction

Clascoterone Cream (Winlevi) for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs ...
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):202-4 |  Show IntroductionHide Introduction

Initial Therapy of Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jul 05, 2004  (Issue 1186)
and an angiotensin-receptor blocker (ARB) have intensified the debate. ALLHAT — ALLHAT (Antihypertensive and Lipid ...
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Med Lett Drugs Ther. 2004 Jul 5;46(1186):53-5 |  Show IntroductionHide Introduction

Pitavastatin (Livalo) - The Seventh Statin

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010  (Issue 1343)
comparing its efficacy in lowering serum lipid concentrations to that of other drugs in its class ...
The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan since 2003. All of the statins now available in the US are listed in the table on page 58.
Med Lett Drugs Ther. 2010 Jul 26;52(1343):57-8 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
tract infection, increased blood creatinine phosphokinase, lipid level increases, rash, acne, headache ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024  (Issue 1703)
55.20 bradycardia and lipid changes Beta-Adrenergic Blockers with Alpha-Blocking Properties Carvedilol ...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8   doi:10.58347/tml.2024.1703a |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
differences in multiple quality-of-life measures (depression, fatigue, etc), body weight, or lipid ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
tofacitinib levels and should be avoided.31 monitoring of complete blood counts, lipid levels, and liver ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction